Market News AIOpen the app

Neurocrine Biosciences said studies on valbenazine for Tourette syndrome didn’t show clear results, so they might stop developing it.

TrialRead the original at wallstreet-online.de
Bad for NBIX

Neurocrine is unlikely to keep developing valbenazine for Tourette syndrome because the main test did not show a statistically significant result. Some study results favored treatment, and the medicine remains approved for tardive dyskinesia.

NBIX · Neurocrine Biosciences

AI read · Bad for NBIX

The AI's read

That removes a possible use for a medicine Neurocrine already sells for tardive dyskinesia. Some study results favored treatment, but the main test did not show a statistically reliable effect. The existing approval for tardive dyskinesia remains in place.

Get alerts for NBIX

Follow Neurocrine Biosciences (NBIX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NBIX
Free on the App Store and Google Play, or on the web.